

Decoupling Immunotherapy Toxicity and Cancer Response

NCT07382752

Status RECRUITING
Sponsor M.D. Anderson Cancer Center
Enrollment 1,200 participants

Key Eligibility Criteria

Inclusion (2)

- Age e 18 years
- Plan to start immune checkpoint inhibitor for cancer therapy

Exclusion (2)

- No baseline blood collection prior to initiation
- At time of evaluation not determined to be a good candidate for evaluation of outcome events by the principal investigator

Locations (1 total)

The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States